News Release PathoQuest Appoints Dr. Klaus Binder to Company’s Board of Directors PathoQuest, the leading expert in GMP next-generation sequencing (NGS) services for biosafety testing, has announced that Klaus Binder, PhD has been appointed as a non-executive director...
Press Release Oxford Nanopore and PathoQuest announce next step of strategic collaboration to bring to market the first sequencing-based quality control test for biopharma genetic characterisation Nanopore sequencing combined with PathoQuest expertise offers a new...
VLOGS Video Blog – SENSITIVITY, SCALABILITY AND SPEED: The Value of Next Generation Sequencing (NGS) for Identity Testing of Plasmids & Viral Vectors Contact us or email us at contact@pathoquest.com if you would like to learn more about our identity testing...
Press Release Oxford Nanopore and PathoQuest announce the first steps in a strategic collaboration to bring the first GMP-accredited, nanopore-based biologics genetic characterisation test to market Nanopore sequencing offers a transformational new approach for robust...
News Release PathoQuest Reiterates its Strategic Growth Plans by Appointing Daniel Spasic to the Board Daniel Spasic, a highly experienced lifescience business leader, has been appointed as a non-executive director to the board of PathoQuest. With over 25 years of...
News Release The updated ICH Q5A(R2) draft guidance has been released PathoQuest, a leader in the development and provision of Next Generation Sequencing (NGS) testing services for the biopharmaceutical industry, is excited to announce that the updated ICH Q5A(R2)...